Response to Comments: MolDX: Xpresys Lung

This administrative notice documents that the MolDX: Xpresys Lung LCD (DL37134) completed its comment period (2017-02-06 to 2017-03-23) with no provider comments, underwent a notice period (2017-05-25 to 2017-07-09), and became final on 2017-07-10. No clinical coverage criteria, limitations, documentation requirements for claims, or frequency limits are specified in this response-to-comments notice.

"Comment period for DL37134 (MolDX: Xpresys Lung) ran from 2017-02-06 to 2017-03-23 and no comments were received from the provider community."

Sign up to see full coverage criteria, indications, and limitations.